Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
The administration of monoclonal antibodies (MoAbs) can result in infusion reactions of various grades; severe reactions are seen in approximately 3% of patients after infusions of cetuximab (fatalities occur in approximately 0.1% of patients). We report a case of a patient who had a severe reaction to cetuximab (a murine MoAb) who then received panitumumab (a human MoAb) and tolerated it without any infusion reaction.
Cartwright
Thomas H
TH
Ocala Oncology, Ocala, FL 34474, USA. thomas.cartwright@usoncology.com
Genther
Renee
R
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; D000068818:Cetuximab